Our point of view on the market forces shaping biopharma transactions, published as short, data-driven briefs.
More than $20B in AI-biotech deal value has poured into drug discovery since 2020, while roughly 80% of trials face enrollment delays: clinical operations remains the industry's largest unaddressed value leak.
Royalty financing has scaled to $32B+ but still represents under 10% of biopharma funding: a structural mismatch between how capital is raised at the company level and how it needs to be deployed at the asset level.
Roughly 100 assets are expected to drive ~80% of $200B in incremental industry revenue through 2030, leaving a widening set of clinically validated, capital-starved assets overlooked.
Asia now drives 43% of the global innovative drug pipeline, up from 28% five years ago, and accounted for more than 85% of pipeline growth in 2024. The competitive edge is shifting from asset access to underwriting rigor.
Biopharma M&A volume is down 40–50% from 2021 levels, not because the science failed, but because expectations, capital assumptions, and scope never recalibrated to what the data actually supports.
Tell us about your asset, target, or strategic challenge. We'll follow up within one business day.
Start a Conversation →